跳至主要内容
临床试验/NCT03445884
NCT03445884已完成2 期

68Ga-NODAGA-E[c(RGDγK)]2: a Novel Positron Emission Tomography (PET) Tracer for in Vivo Molecular Imaging of Myocardial Angiogenesis Following Myocardial Infarction

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2018年2月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
42
试验地点
1
主要终点
To evaluate myocardial angiogenesis

研究概览

简要总结

The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with myocardial infarction and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis.

详细描述

Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the initial repair, the tissue undergoes a remodeling phase to compensate for the damaged area. This re-modeling phase can change the structure end geometry of the heart resulting in lower ejection fraction, leading to cardiac dysfunction, which eventually leads to heart failure. Understanding and ideally modifying the reparative mechanisms following myocardial infarction is increasingly important and may lead to improved outcome.

If the heart suffers from ischemia following an acute coronary event, the tissue reacts strongly to the hypoxia. The body will as a compensatory mechanism create new vessel to provide the tissue with oxygen. This is known as the biological process of angiogenesis. This complex process involves different angiogenic and pro-fibrotic transcription factors that initiate the restoration of capillaries by sprouting from the existing endothelial cells in response to hypoxia.

Time seem essential to protect and save the myocardium. An early onset of cytokines and growth factors is associated with a decline in cardiomyocytes apoptosis, smaller infarct areas, and decreased ventricular dilation. Therefore, an early induction of angiogenesis seems important for a good prognosis of the patient.

Integrin αvβ3 is a transmembrane cell surface receptor that is markedly upregulated in states of angiogenesis. It facilitates migration and proliferation and thereby allowing cells to respond to extracellular environment. Integrin αvβ3 is thus a key player in the angiogenic process. The integrin αvβ3 has a binding site for an RGD peptide (Arg-Gly-Asp motif) and this can be targeted by PET tracers.

RGD-based PET tracers have been shown to accumulate at the site of myocardial necrosis in both human and animal studies. The uptake seems to peak a few weeks after the infarction and may correlate to recovery of cardiac function and thus serve as a prognostic marker.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 50 years
  • Acute myocardial infarction Group:
  • Verified first-time acute myocardial infarction treated with PCI
  • Control Group:
  • Previous healthy
  • No known cardiac disease

排除标准

  • No prior history of acute coronary infarction
  • No prior history of Heart surgery
  • Not treated with anti-angiogenic medicine
  • Subject with pacemaker, cochlear implant or insulin pump
  • Pregnancy
  • Lactation
  • Severe claustrophobia
  • Severe obesity (weight above 140kg)
  • If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET_tracer
  • If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial
  • If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨
  • Tupe I or II diabetes

研究组 & 干预措施

Acute myocardial infarctions group

Experimental

200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.

干预措施: 68Ga-NODAGA-E[c(RGDyK)]2 (Drug)

Control group

Active Comparator

200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.

干预措施: 68Ga-NODAGA-E[c(RGDyK)]2 (Drug)

结局指标

主要结局

To evaluate myocardial angiogenesis

时间窗: 30-35 days

Analysing uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 Positron Emission Tomography in myocardial infarction after PCI

次要结局

  • Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and functional recovery(30-35 days)
  • Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and myocardial perfusion(30-35 days)
  • Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and viability(30-35 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Simon Bentsen

Medical Doctor

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验